In glioblastoma, CD44 expression conferred growth advantages and therapeutic resistance (Xu et al. 2010) and it remains to be resolved whether analogous mechanisms are also active in MB, in particular in the context of c-Met interaction with CD44v6. This evidence concerns the gene CD44 and glioblastoma.